Related Experiment Video
Updated: Jun 15, 2026
Establishment of Tumor Organoids, Carcinoma-Associated Fibroblasts, and Counterpart Fibroblasts from the Same Esophageal Cancer Patient
Published on: April 3, 2026
The low expression of CD80 correlated with the vascular endothelial growth factor in esophageal cancer tissue
1Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Jinan 250117, Shandong Province, China. sdthywf@yahoo.com.cn
Aims:
To analyze the mRNA and protein expression of CD80 and vascular endothelial growth factor (VEGF) in esophageal cancer (EC) tissue, investigate the causes of esophageal cancer cell escape from immune surveillance.
Methods:
We detected the CD80 and VEGF mRNA with reverse transcription polymerase chain reaction (RT-PCR), CD80 protein with flow cytometry, VEGF protein with immunohistochemistry in the cancer tissues in 118 EC patients, and the normal esophageal tissue as controls.
Results:
The expression of CD80 mRNA and protein in cancer tissues were lower than that in the controls (p<0.01, respectively), The CD80 protein expression in poor differentiation was lower than that in the well and moderate (P<0.01), in the patients with lymph node metastasis lower than that with no metastasis (P=0.01), in stage IIIA patients lower than that in stages I and II patients (P=0.04); the VEGF mRNA and protein expression were just right opposite. The mean survival time in the CD80 positive group was significantly longer than that in the negative (p=0.041); while in VEGF positive group was lower than that in the negative (p=0.046). The CD80 expression of mRNA and protein were correlated negatively with VEGF in the cancer tissues (r=-0.82, -0.87, respectively).
Conclusion:
It is suggested that CD80 was impaired in the EC tissues and correlated with the clinicopathological characteristics and prognosis, which indicated the dysfunction of immune system and enhancing the progression of EC. The low expression of CD80 correlated with the overexpression of VEGF.
Insights
In esophageal cancer (EC), CD80 expression is reduced, correlating with poor prognosis and immune dysfunction. Conversely, vascular endothelial growth factor (VEGF) is overexpressed, promoting tumor progression.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Esophageal cancer (EC) progression is linked to immune evasion.
- Understanding the roles of CD80 and vascular endothelial growth factor (VEGF) is crucial for EC research.
Purpose of the Study:
- To analyze CD80 and VEGF expression in EC tissues.
- To investigate the relationship between these molecules and immune surveillance in EC.
Main Methods:
- CD80 and VEGF mRNA levels were measured using RT-PCR.
- CD80 protein was quantified via flow cytometry.
- VEGF protein was assessed using immunohistochemistry in 118 EC patients and controls.
Main Results:
- CD80 mRNA and protein expression were significantly lower in EC tissues compared to controls.
- VEGF mRNA and protein expression showed the opposite trend.
- Lower CD80 expression correlated with advanced tumor stage, lymph node metastasis, and poorer differentiation.
- Higher VEGF expression correlated with shorter survival times.
- A strong negative correlation was observed between CD80 and VEGF expression (r=-0.82 for mRNA, r=-0.87 for protein).
Conclusions:
- CD80 is impaired in EC, contributing to immune dysfunction and disease progression.
- The downregulation of CD80 is associated with clinicopathological characteristics and prognosis in EC.
- Low CD80 expression is linked to the overexpression of VEGF in esophageal cancer.
